Bioport Nikovari Bio Tech Oy | CROSSLINK 2% | PLUS 1,5%

IN EARLY INTERVENTION ORTHOPEDIC CARE

BIOPORT

PROFESSIONAL SOLUTIONS

Download Presentation

Nikovari Bio Tech Oy

SOLUTIONS FOR LIFE

Nikovari Bio Tech Oy is a biotechnology company established in Helsinki, Finland in 2017, backed with a combined experience and track record of 20 years in orthopaedics of the founding team. We are committed to delivering meaningful solutions in early intervention orthopedic care including osteoarthritis pain management and other joint preservation options to people suffering from degenerative joint pathology to relieve their pain and improve their quality of life.

INTRA-ARTICULAR INJECTIONS FOR A LONG TERM TREATMENT OF SYMPTOMATIC OSTEOARTHRITIS

PAIN RELIEF, RESTORED MOBILITY AND JOINT RECOVERY TO MEET ALL YOUR CLINICAL NEEDS

BIOPORT® CROSSLINK 2%

60 mg hyaluronic acid | 90 mg chondroitin sodium sulfate per syringe
Only one injection per treatment

BIOPORT® PLUS 1,5%

30 mg hyaluronic acid per syringe
Three injections per treatment

OSTEOARTICULAR PATHOLOGIES AFFECT ABOUT 10% OF THE GLOBAL POPULATION.

Among these, osteoarthritis is one of the most frequent disorders, which is estimated to affect at least 57 million people in Europe alone.

BIOPORT® PLUS 1,5%

It replaces or reinforces the synovial fluid in the joints and is recommended for symptomatic treatment of synovial joint degeneration, including bone and joint inflammation.

Composition: Sodium hyaluronate
Concentration: 30 mg/2ml 1.5%
Administration total: 3 syringes, 1 week apart from each other
Average molecular weight: 1.8-2.6 MDa
30 MG HYALURONIC ACID PER SYRINGE (15 MG / ML) 2 ML PRE-FILLED SYRINGE

BIOPORT® PLUS 1,5% /// PROPERTIES

Three injections per treatment

Highly purified 30mg hyaluronic acid per syringe

Highest degree of compatibility with properties of synovial fluid

Free from animal proteins

Delivered in pre-filled glass syringe Becton Dickinson

SODIUM HYALURONATE

In medical devices containing sodium hyaluronate for the viscoelastic supplementation of the synovial fluid, it is very important for the gel to imitate to the highest extent the synovial fluid and to be as close as possible to its properties, degrading as hard as possible in the joint.

INDICATION

As a viscoelastic supplement or a replacement for synovial fluid in human knee joints
For symptomatic treatment of knee osteoarthritis

EFFECTS

Lubricant and mechanical support
Improvement of joint mobility

APPLICATION

Depending on the degree of discomfort, about one injection per week, about 3 injections per treatment course. The effect can be sustained over a period of about 6 months.

BIOPORT PROVIDES PAIN RELIEF, LUBRICATION AND MECHANICAL SUPPORT.

BIOPORT is a sterile, viscoelastic solution for intra-articular injection.

BIOPORT® CROSSLINK 2%

It is a sterile viscoelastic solution for intra-articular injection, the two cross-linked biological polymers, sodium hyaluronate and chondroitin sodium sulfate involves.

Composition: Sodium hyaluronate, Chondroitin sodium sulfate
Concentration: 60 mg/90 mg/3ml 2%/3%
Administration total: 1 syringe at 6 months
Average molecular weight: 3MDa
Elasticity mode G’ in rest 0,5 Hz / running 2,5 Hz: 242 Pa / 468 Pa
Viscosity mode G“ at rest/running: 180 Pa/220 Pa
60 mg hyaluronic acid per syringe (20 mg / ml) 90 mg chondroitin sodium sulfate (30 mg / ml)

3 ml pre-filled syringe

BIOPORT® CROSSLINK 2% /// PROPERTIES

Only one injection per treatment

Highly concentrated: 60mg hyaluronic acid per syringe with chondroitin for cartilage tissue

Delivered in pre-filled glass syringe Becton Dickinson

CHONDROITIN SULFATE

Protects the cartilage and decreases inflammatory activity in the region affected by osteoarthritis (OA). Contributes to physical cross-linking of the hyaluronate chains being binded thereto in a 1:1 ration, increasing in this way the properties of sodium hyaluronate.